MiR-486-5p negatively regulates oncogenic NEK2 in hepatocellular carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• NEK2 is a serine/threonine kinase involved in cell cycle regulation.
• Hepatocellular carcinoma (HCC) is a major global health concern with variable patient outcomes.
• Identifying prognostic biomarkers is crucial for improving HCC patient survival after liver transplantation.

Purpose of the Study:

• To investigate the prognostic significance of NEK2 expression in HCC patients post-liver transplant.
• To explore the role of microRNAs (miRNAs) in regulating NEK2 expression in HCC.
• To elucidate the functional impact of NEK2 on HCC cell behavior and tumor growth.

Main Methods:

• Analysis of Oncomine database for NEK2 expression in HCC tissues.
• Correlation analysis between NEK2 expression and clinical parameters (tumor size, grade, invasion).
• In vitro assays (proliferation, colony formation, migration, invasion) and in vivo xenograft models in mice.
• Luciferase reporter assays to confirm direct binding of miR-486-5p to NEK2 3'UTR.

Main Results:

• NEK2 expression is significantly upregulated in HCC tissues compared to normal liver tissues.
• High NEK2 expression correlates with larger tumor size, higher pathological grade, and vascular invasion.
• Elevated NEK2 levels are associated with poorer patient prognosis and serve as an independent prognostic factor for HCC survival.
• Overexpression of NEK2 enhances HCC cell proliferation, migration, and invasion, and promotes tumor growth in vivo.
• MiR-486-5p directly targets and suppresses NEK2 expression, with an inverse correlation observed in HCC patients.

Conclusions:

• NEK2 is a critical prognostic biomarker for HCC patients undergoing liver transplantation.
• MiR-486-5p acts as a tumor suppressor by inhibiting NEK2 in HCC.
• Targeting the NEK2/miR-486-5p axis may offer a novel therapeutic strategy for HCC treatment.